Bafna Pharmaceuticals Limited has submitted to the Exchange, the outcome of the Board Meeting held on November 11, 2025 along with the Unaudited financial results and Limited Review Report for the Quarter and Half Year ended September 30, 2025.
BAFNAPH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bafna Pharmaceuticals has filed its unaudited financial results for the quarter and half year ended September 30, 2025, along with the Limited Review Report from its statutory auditors. The board meeting to approve these results was held on November 11, 2025. The headline itself does not disclose specific financial numbers, revenue, profit, or margin figures. A Limited Review Report is a standard auditor review required for quarterly results and is less detailed than a full audit.
Investors should look at the detailed financial results file to assess revenue growth, profit trends, and margin performance. The filing itself is a routine regulatory disclosure and is not, on its own, a positive or negative signal for the stock.